Trial · NCT04649489
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04649489, Phase 3, Active not recruiting, Jia Fan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev. Trials, record NCT04649489. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04649489
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- NCT number
- NCT04649489
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 501 participants, estimated
- Lead sponsor
- Jia Fan
- Conditions
- Venous Thrombosis
- Interventions
- Atezolizumab & Bevacizumab, Surgery followed by atezolizumab and bevacizumab
- First posted
- 2020-12-02
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TTF | 24 months | Time-to-treatment failure (TTF) after randomization, defined as the time from randomization to the first documented treatment failure (i.e., local recurrence or progression, EHS, or death from any cause). Tumor response will be determined by the IRF according to RECIST v1.1 |
| Secondary | OS | 24 months | Overall survival (OS) after randomization, defined as the time from randomization to death from any cause |
| Secondary | OS rate | 24 months | OS rate at 12 months, 18 months and 24 months, defined as the proportion of patients who have not experienced death from any cause at 12, 18 and 24months after randomization, respectively |
| Secondary | TTF | 24 months | TTF after randomization as determined by the investigator according to RECIST v1.1 |
| Secondary | TTF | 24 months | TTF after randomization as determined by the IRF and the investigator according to HCC mRECIST |
| Secondary | Time to EHS | 24 months | Time to EHS after randomization, defined as the time from randomization to first appearance of EHS, as determined by the IRF and the investigator |
| Other | AE/ADR | 24 months | Nature, incidence, severity and seriousness of the adverse events/ADR. Adverse events are graded according to the NCI-CTCAE (Version 5.0) |
| Other | RFS | 24 months | Recurrence-free survival (RFS) after randomization (Arm A), defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by the IRF and the investigator, or death from any cause (whichever occurs first) |
| Other | TTR | 24 months | Time-to-Recurrence (TTR) after randomization (Arm A), defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC, as determined by the IRF and the investigator |
| Other | R0 rate | 24 months | R0 rate (Arm A), defined as the proportion of patients who accomplish the complete resection of tumor with pathologically confirmed negative margin |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42624156 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04649489
GET https://conductscience.org/api/trials/v1/NCT04649489/registered